Noscendo GmbH develops bioinformatic solutions to identify and assess pathogens in bloodstream associated and related infections. The proprietary diagnostic platform has been validated together with leading German clinicians and will be provided in the area of bloodstream infections. For this, Noscendo works together with leading hospitals, development partners, logistics providers, innovation-driven health service providers and health insurance funds.
Peter Haug is CFO and Head of Business Development & Licensing at Noscendo GmbH. Since 2011, he is specialized in developing start-up companies from renowned Research Organisations.
Prior to this he has built up a Contract Development and Manufacturing Organization with more than €250 million sales and 1,500 employees via acquisitions from AstraZeneca, Bristol-Myers Squibb, Genzyme and Roche, and gained 7 years’ experience in international top management consultancies.
NGS-based pathogen detection in the context of AMR, CoVid-19 and beyond
Noscendo GmbH is a bioinformatics startup at Duisburg (Germany), financed by Earlybird, Paua Ventures, Wieland Capital, HTGF and private investors. Noscendo is operating its NGS-based laboratory at Tübingen-Reutlingen and has established CE-approved DISQVER® testing service for Next-Generation-Sequencing (NGS)-based identification of bloodstream-related infections.
The corresponding proprietary platform technology for bioinformatics services is clinically being used as positive identification of life-threatening pathogens in acute infection settings such as endocarditis, severe sepsis, haemato¬-oncology and others. Quick identification of the causative pathogen enables very specific, targeted antimicrobial therapy. Especially immune-compromised patients may develop infections with rare pathogens which hardly can be diagnosed by the current diagnostic tools, if at all.
High risk populations at maximum care hospitals such as oncology and transplant patients as well as neonates also extremely benefit from exclusion of pathogen infections via negative NGS-based test results, Negative identification of pathogens limits the usage of antibiotics to the necessary clinical minimum and avoids unnecessary side-effects of iv-antibiotic treatments.
Both use cases support reduction of antimicrobial resistances in hospitals and especially in intensive care settings (ICUs).
Germanys largest health insurance Techniker Krankenkasse has just started a selective contract for reimbursement of this diagnostic innovation and is expecting more effective anti-infective treatment of the intensive care patients combined with a reduction of antimicrobial resistances in maximum care hospitals: https://www.aerztezeitung.de/Politik/Neuer-Versorgungsvertrag-der-TK-Liquid-Biopsy-spuert-Keime-auf-409497.html
In the context of CoVid-19, NGS-based pathogen detection identifies potential superinfections of bacteria, DNA viruses or fungi on top of CoVid-19 in ICUs. Various corresponding analyses have been performed throughout 2020 by Noscendo.